NEW YORK, NY--(Marketwire - July 17, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today the addition of two senior executives as the Company accelerates its Phase III clinical trial towards completion. Mark Morrison, M.D., Ph.D. joins Delcath as Chief Medical Officer to oversee the expansion of clinical activity of the Company’s first Phase III clinical trial. He replaces Dr. Seymour Fein in this position. Mr. John Talarico joins Delcath in the newly created position of Senior Vice President Regulatory Affairs and Quality Systems.
